Results 161 to 170 of about 30,320,198 (205)

Cancer cell‐intrinsic type 1 interferon: production, signaling, and outcomes within sex‐biased, female malignancies

open access: yesMolecular Oncology, Volume 20, Issue 9, Page 2135-2162, September 2026.
The cell‐autonomous roles of interferon type 1 vary based on duration and intensity. While acute, robust signaling results in cancer cell cytotoxic effects, sustained, low‐level signaling is associated with tumor‐promoting effects. This review summarizes current research of IFN‐1 in cancer and within the clinical setting, with an emphasis on female ...
Ashlyn Conant   +7 more
wiley   +1 more source

Pemt Inhibition‐Mediated Vdac1 Oligomerization Regulates Mitochondrial Dysfunction, Apoptosis, and Inflammation in High‐Fat Diet‐Derived Liver Injury

open access: yesAdvanced Science, Volume 13, Issue 50, 7 September 2026.
ABSTRACT High‐fat diet (HFD)‐induced hepatic injury represents a pathology observed across vertebrates, yet the underlying mechanisms remain incompletely understood. Herein, the present study identifies phosphatidylethanolamine methyltransferase (Pemt), a key enzyme in phosphatidylcholine synthesis, as a critical regulator of mitochondrial homeostasis ...
Xianyong Bu   +11 more
wiley   +1 more source

NAD+ Metabolism Licenses Zygotic Genome Activation via PARP7‐Mediated ADP‐Ribosylation of UHRF1 in Mouse Early Embryos

open access: yesAdvanced Science, Volume 13, Issue 51, 14 September 2026.
This study uncovers a metabolic‐epigenetic axis licensing zygotic genome activation (ZGA) in mouse embryos. A developmental decline in NAD+ levels activates PARP7, which mono‐ADP‐ribosylates and stabilizes UHRF1. This modification promotes the establishment of permissive histone acetylation marks, thereby facilitating timely ZGA.
Guangyi Cao   +13 more
wiley   +1 more source

PARP Inhibitors plus Anlotinib as Bridging Therapy for Armored CAR‐T Cells in Ovarian Cancer Enhances Infiltration and Antitumor Efficacy

open access: yesAdvanced Science, Volume 13, Issue 53, 24 September 2026.
This study shows that a PARP inhibitor combined with anlotinib, administered as bridging therapy, preconditions the tumor microenvironment to enhance the infiltration and antitumor activity of subsequently infused CAR‐T cells across preclinical ovarian cancer models, supporting bridging therapy as a promising strategy to address limited CAR‐T cell ...
Huayi Li   +20 more
wiley   +1 more source

Poly (ADP-ribose) polymerase 1 expression in fibroblasts of Down syndrome subjects

open access: yesOpen Medicine, 2013
Salemi Michele   +10 more
doaj   +1 more source

Organelle Crosstalk and Metabolic Reprogramming in Idiopathic Pulmonary Fibrosis: Mechanisms and Therapeutic Implications

open access: yesCell Biochemistry and Function, Volume 44, Issue 9, September 2026.
ABSTRACT Idiopathic pulmonary fibrosis (IPF) is a fatal interstitial lung disease of unknown cause, marked by excessive deposition of extracellular matrix (ECM) components such as collagen. This pathological accumulation results in progressive destruction of the lung architecture and ultimately leads to respiratory failure.
Yining Zhang   +4 more
wiley   +1 more source

The Significance of cGAS‐STING Signaling in Response to Oncogenic Viruses

open access: yesCell Biochemistry and Function, Volume 44, Issue 9, September 2026.
ABSTRACT The cyclic GMP‐AMP synthase (cGAS)‐stimulator of interferon genes (STING) signaling pathway, as a key DNA sensor, plays a significant role in the regulation of innate immune responses. This pathway can be activated by sensing abnormal DNA, and is of great significance for resisting the invasion of pathogenic microorganisms and maintaining ...
Limei Guo   +4 more
wiley   +1 more source

Reactive Oxygen Species in Breast Cancer: From Redox Dysregulation to ROS‐Responsive Therapeutics

open access: yesCell Biochemistry and Function, Volume 44, Issue 9, September 2026.
ABSTRACT Breast cancer is the most frequently diagnosed malignancy among women worldwide, with 2.3 million new cases and approximately 670,000 deaths reported in 2022 alone. Despite advances in therapy, metastasis and acquired drug resistance remain major clinical challenges.
Marija Nikolovska   +5 more
wiley   +1 more source

Clinical Benefit of Pembrolizumab in Lynch Syndrome‐Associated Advanced Ovarian Cancer With Germline MSH6 Variant: A Case Report

open access: yesClinical Case Reports, Volume 14, Issue 9, September 2026.
ABSTRACT This case highlights the importance of genetic evaluation during treatment in young patients with advanced ovarian cancer. Lynch syndrome caused by a germline MSH6 pathogenic variant was diagnosed during first‐line maintenance therapy, and pembrolizumab achieved a durable response in recurrent disease.
Tomomi Yokozawa   +7 more
wiley   +1 more source

A Novel BRCA1 Pathogenic Variant in Tunisian Patient With High Grade Ovarian Cancer: Favorable Therapeutic Response to Olaparib

open access: yesCancer Reports, Volume 9, Issue 9, September 2026.
ABSTRACT Background Ovarian cancer is one of the leading causes of death from gynecological cancer worldwide. Genetic mutations in genes involved in key cellular functions such as BRCA1/2 play a central role in tumorigenesis and have major implications for targeted therapeutic strategies, especially the use of poly (ADP‐ribose) polymerase (PARP ...
Nihel Ammous‐Boukhris   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy